Literature DB >> 3802594

The analgesic problem in the Federal Republic of Germany: analgesic consumption, frequency of analgesic nephropathy and regional differences.

W Pommer, G Glaeske, M Molzahn.   

Abstract

The recent withdrawal of phenacetin from the pharmaceutical market in the FRG has stimulated the discussion of the extent of analgesic abuse and analgesic nephropathy (AN). Data from wholesale statistics, given here, revealed in the FRG population a high yearly per-capita consumption of analgesics (18.2 g), mostly used in mixed compounds. According to standardized data, the FRG ranks first among the north European countries. We suggest that the prevalence data given from the EDTA-registry (4.6% of the endstage renal population) underestimates the real extent of AN. AN in the FRG shows a north-to-south decline and is most prevalent in northern areas and West Berlin. It is assumed that the analgesic dilemma in the FRG is identical to the dilemma in Switzerland and Belgium.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3802594

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  Consumption of analgesics and anti-inflammatory drugs in the nordic countries between 1978-1988.

Authors:  R Ahonen; H Enlund; T Klaukka; J Martikainen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man.

Authors:  H Bippi; J C Frölich
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

3.  [The effect of various factors on the progression of kidney insufficiency cause by analgesic nephropathy].

Authors:  J Kindler; G Giani; S Handt; H G Sieberth
Journal:  Klin Wochenschr       Date:  1990-11-09

Review 4.  Use and abuse of over-the-counter analgesic agents.

Authors:  F V Abbott; M I Fraser
Journal:  J Psychiatry Neurosci       Date:  1998-01       Impact factor: 6.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.